Gynecologic Cancer | Norton Healthcare

Indication: Gynecologic Cancer

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator?s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Ovarian

Sub-indication: Ovarian, Fallopian tube

Drug Study

Principal Investigator: Mary Gordinier, M.D.
Norton Cancer Institute

Sponsor: ImmunoGen, Inc.

Learn more at ClinicalTrials.gov

Email for more information: GYN-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.